Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
keynote 158 | 0.34 | 1 | 6024 | 9 | 11 |
keynote | 0.74 | 0.4 | 8094 | 86 | 7 |
158 | 1.39 | 0.7 | 6978 | 55 | 3 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
keynote 158 | 0.38 | 0.2 | 9680 | 64 |
keynote 158 trial | 0.7 | 0.9 | 7624 | 93 |
keynote 158 endometrial cancer | 0.72 | 0.9 | 8531 | 79 |
keynote 158 tmb | 1.91 | 0.5 | 3547 | 43 |
keynote 158 cervical cancer | 1.14 | 0.3 | 5173 | 26 |
keynote 158 endometrial | 1.21 | 0.1 | 6285 | 82 |
keynote 158 protocol | 1.32 | 0.2 | 4795 | 55 |
keynote 158 studie | 0.06 | 0.4 | 8480 | 54 |
keynote 158 pembrolizumab | 1.37 | 0.1 | 3823 | 21 |
keynote 158 pancreatic cancer | 0.1 | 0.7 | 9378 | 84 |
keynote 158 sclc | 1.99 | 0.4 | 1061 | 96 |
keynote 158 clinical trials | 0.5 | 0.3 | 9239 | 96 |
keynote 158 tmb high | 1.03 | 0.3 | 3977 | 72 |
phase 2 keynote 158 | 0.11 | 0.5 | 4774 | 89 |
keynote 158 fda | 0.21 | 0.3 | 2283 | 27 |